Akash Tewari
Stock Analyst at Jefferies
(2.75)
# 1,641
Out of 5,182 analysts
66
Total ratings
42%
Success rate
8.37%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Buy | $47 → $85 | $71.90 | +18.22% | 2 | Apr 13, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $151 → $138 | $102.06 | +35.21% | 4 | Mar 10, 2026 | |
| VRTX Vertex Pharmaceuticals | Initiates: Buy | $580 | $426.01 | +36.15% | 1 | Mar 10, 2026 | |
| AMGN Amgen | Initiates: Hold | $350 | $340.18 | +2.89% | 1 | Mar 10, 2026 | |
| GILD Gilead Sciences | Initiates: Buy | $180 | $127.75 | +40.90% | 1 | Mar 10, 2026 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $52.95 | -33.90% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $72.23 | +32.91% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $744.44 | +11.63% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $25.15 | +3.38% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $10.29 | -2.82% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $68 | $57.78 | +17.69% | 4 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $53.81 | +76.56% | 2 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 → $16 | $14.95 | +7.02% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $177 → $189 | $128.04 | +47.61% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $40.95 | +95.36% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $868.27 | +16.90% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $33.73 | +48.24% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $86.49 | -13.28% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $26.79 | +45.58% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $13.26 | +35.80% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $783.74 | -34.54% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $110.23 | +13.40% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $28.56 | -61.48% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.88 | +804.26% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $61.60 | +21.75% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $520.09 | -70.97% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $44.65 | -37.29% | 3 | Oct 7, 2021 |
Spyre Therapeutics
Apr 13, 2026
Maintains: Buy
Price Target: $47 → $85
Current: $71.90
Upside: +18.22%
BioNTech SE
Mar 10, 2026
Maintains: Buy
Price Target: $151 → $138
Current: $102.06
Upside: +35.21%
Vertex Pharmaceuticals
Mar 10, 2026
Initiates: Buy
Price Target: $580
Current: $426.01
Upside: +36.15%
Amgen
Mar 10, 2026
Initiates: Hold
Price Target: $350
Current: $340.18
Upside: +2.89%
Gilead Sciences
Mar 10, 2026
Initiates: Buy
Price Target: $180
Current: $127.75
Upside: +40.90%
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $52.95
Upside: -33.90%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $72.23
Upside: +32.91%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $744.44
Upside: +11.63%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $25.15
Upside: +3.38%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $10.29
Upside: -2.82%
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $57.78
Upside: +17.69%
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $53.81
Upside: +76.56%
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $14.95
Upside: +7.02%
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $128.04
Upside: +47.61%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $40.95
Upside: +95.36%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $868.27
Upside: +16.90%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $33.73
Upside: +48.24%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $86.49
Upside: -13.28%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $26.79
Upside: +45.58%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $13.26
Upside: +35.80%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $783.74
Upside: -34.54%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $110.23
Upside: +13.40%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $28.56
Upside: -61.48%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.88
Upside: +804.26%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $61.60
Upside: +21.75%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $520.09
Upside: -70.97%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $44.65
Upside: -37.29%